Mulpleta (Lusutrombopag) Patent Expiration, LOE Window & CMS Spending

Mulpleta (Lusutrombopag) by Vancocin Italia Srl: FDA Orange Book core substance LOE 2030-01-21 (last listed 2031-09-29), 0 AB generics, $492K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorVancocin Italia Srl
FDA Application & PathwayN210923 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2030-01-21
Last Listed Patent or Exclusivity Date2031-09-29
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$492K
2024 Medicare Part D Spend$205K
2024 Medicaid Spend$287K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel